Carsten Kobe

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Andreas Engert, Heinz Haverkamp, Carsten Kobe et al. · The Lancet · 2012 · 632 citations

Medicine, Oncology, Radiation Oncology +15

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Peter Borchmann, Helen Goergen, Carsten Kobe et al. · The Lancet · 2017 · 386 citations

Medicine, Oncology, Radiation Oncology +12

Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

Markus Dietlein, Carsten Kobe, Georg Kuhnert et al. · Molecular Imaging and Biology · 2015 · 362 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Positron Emission Tomography–Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group

Michael Fuchs, Helen Goergen, Carsten Kobe et al. · Journal of Clinical Oncology · 2019 · 229 citations

Medicine, Nuclear Medicine, Oncology +14

Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma

Carsten Kobe, Markus Dietlein, Jeremy Franklin et al. · Blood · 2008 · 204 citations · Full text

Medicine, Oncology, Radiology +17